Marco Giorgio

Prof. Marco Giorgio

Department of Biomedical Sciences, University of Padua, Via Ugo Bassi 58/B, 35131 Padova, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Redox Biology
Verified
Journal Article
Open access
Marco GiorgioMarco Giorgio
Marco Giorgio
GDGaetano Ivan Dellino
Gaetano Ivan Dellino
VGValentina Gambino
Valentina Gambino
NRNiccolo’ Roda
Niccolo’ Roda
PPPier Giuseppe Pelicci
Pier Giuseppe Pelicci
Chemical modifications of DNA and RNA regulate genome functions or trigger mutagenesis resulting in aging or cancer. Oxidations of macromolecules, including DNA, are common reactions in biological systems and often part of regulatory circuits rather than accidental events. DNA alterations are particularly relevant since the unique role of nuclear and mitochondrial genome is coding enduring and inheritable information. Therefore, an alteration in DNA may represent a relevant problem given its transmission to daughter cells. At the same time, the regulation of gene expression allows cells to continuously adapt to the environmental changes that occur throughout the life of the organism to ultimately maintain cellular homeostasis. Here we review the multiple ways that lead to DNA oxidation and the regulation of mechanisms activated by cells to repair this damage. Moreover, we present the recent evidence suggesting that DNA damage caused by physiological metabolism acts as epigenetic signal for regulation of gene expression. In particular, the predisposition of guanine to oxidation might reflect an adaptation to improve the genome plasticity to redox changes.

1 May 2017 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
KPKatia Petroni
Katia Petroni
MTM. Trinei
M. Trinei
MFM. Fornari
M. Fornari
VCV. Calvenzani
V. Calvenzani
AMA. Marinelli
A. Marinelli
Marco GiorgioMarco Giorgio
Marco Giorgio

31 January 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MRMicol Ravà
Micol Ravà
ADAleco D’andrea
Aleco D’andrea
PNPaola Nicoli
Paola Nicoli
IGIlaria Gritti
Ilaria Gritti
GDGiulio Donati
Giulio Donati
BABruno Amati
Bruno Amati
The antibiotic tigecycline and the BCL2 inhibitor venetoclax cooperate to treat MYC/BCL2 double-hit lymphomas in xenografted mice.

19 February 2022 in Cells
Verified
Journal Article
Open access
PDF file
GPGIUSEPPE PERSICO
GIUSEPPE PERSICO
Francesca CasciaroFrancesca Casciaro
Francesca Casciaro
Stefano AmatoriStefano Amatori
Stefano Amatori
MRMartina Rusin
Martina Rusin
FCFrancesco Cantatore
Francesco Cantatore
Marco GiorgioMarco Giorgio
Marco Giorgio
Background: Epigenetic remodeling is emerging as a critical process for both the onset and progression of Alzheimer’s disease (AD), the most common form of neurodegenerative dementia. However, it is not clear to what extent the distribution of histone modifications is involved in AD. Methods: To investigate histone H3 modifications in AD, we compared the genome-wide distributions of H3K4me3 and H3K27me3 in entorhinal cortices from severe sporadic AD patients and from age-matched healthy individuals of both sexes. Results: AD samples were characterized by typical average levels and distributions of the H3K4me3 and H3K27me3 signals. However, AD patients showed a lower H3K4me3 and higher H3K27me3 signal, particularly in males. Interestingly, the genomic sites found differentially trimethylated at the H3K4 between healthy and AD samples involve promoter regions of genes belonging to AD-related pathways such as glutamate receptor signaling. Conclusions: The signatures of H3K4me3 and H3K27me3 identified in AD patients validate the role of epigenetic chromatin remodeling in neurodegenerative disease and shed light on the genomic adaptive mechanisms involved in AD.

1 March 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
MTMirella Trinei
Mirella Trinei
ACAndrea Carpi
Andrea Carpi
RMRoberta Menabo'
Roberta Menabo'
MSMariangela Storto
Mariangela Storto
MFMonica Fornari
Monica Fornari
Marco GiorgioMarco Giorgio
Marco Giorgio

11 September 2020 in Cells
Verified
Journal Article
Open access
PDF file
NRNiccolò Roda
Niccolò Roda
VGValentina Gambino
Valentina Gambino
Marco GiorgioMarco Giorgio
Marco Giorgio
Metastasis formation accounts for the majority of tumor-associated deaths and consists of different steps, each of them being characterized by a distinctive adaptive phenotype of the cancer cells. Metabolic reprogramming represents one of the main adaptive phenotypes exploited by cancer cells during all the main steps of tumor and metastatic progression. In particular, the metabolism of cancer cells evolves profoundly through all the main phases of metastasis formation, namely the metastatic dissemination, the metastatic colonization of distant organs, the metastatic dormancy, and ultimately the outgrowth into macroscopic lesions. However, the metabolic reprogramming of metastasizing cancer cells has only recently become the subject of intense study. From a clinical point of view, the latter steps of the metastatic process are very important, because patients often undergo surgical removal of the primary tumor when cancer cells have already left the primary tumor site, even though distant metastases are not clinically detectable yet. In this scenario, to precisely elucidate if and how metabolic reprogramming drives acquisition of cancer-specific adaptive phenotypes might pave the way to new therapeutic strategies by combining chemotherapy with metabolic drugs for better cancer eradication. In this review we discuss the latest evidence that claim the importance of metabolic adaptation for cancer progression.